Lamivudine Tablet, Film Coated
Product Images NDC 31722-754

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 31722-754). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Camber1

FDA Label Image

Camber2

FDA Label Image

Lamivudine1

The text describes the proportions of subjects with HIV-1 RNA less than 400 copies/mL at different treatment times (in weeks) for two different doses of Lamivudine. The first dose is 150 mg taken twice daily, while the second dose is 300 mg taken once daily. The graph shows the data for up to 48 weeks of treatment.*

FDA Label Image

Lamivudine150mg

FDA Label Image

Lamivudine300mg

FDA Label Image

Lamivudinestruc

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.